Piramal Enterprises Ltd. has received approval from the FDA for its IND for P7435, a novel, potent and highly selective, oral diacylglycerolacyltransferase 1 (DGAT1) inhibitor for treatment of lipid disorders and diabetes.   P7435 has demonstrated its lipid lowering potential in various preclinical studies, showing a reduction in triglyceride levels, glucose and insulin levels, and decrease in food intake and body weight gain. Piramal has established the safety and tolerability of P7435 in a Pha...